Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Zd 1839 "Iressa"].

J B Meric1, S Faivre, C Monnerat

  • 1Département de médecine, Institut Gustave-Roussy, 39, rue Camille-Desmoulins 94805 Villejuif Cedex.

Bulletin Du Cancer
|February 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unravelling the role of environmentally realistic concentrations of titanium dioxide nanoparticles in altering gametogenesis and gonadal health of female Pacific oysters (Magallana gigas): a histopathological approach.

Aquatic toxicology (Amsterdam, Netherlands)·2025
Same author

Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review.

ESMO open·2024
Same author

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.

Oncoimmunology·2020
Same author

First evaluation of neustonic microplastics in the Macaronesian region, NE Atlantic.

Marine pollution bulletin·2020
Same author

Medical oncologists must get more involved in systemic treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Clinical and translational gastroenterology·2019
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

ZD 1839, an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor, shows antiproliferative effects by blocking signal transduction. Clinical trials indicate manageable toxicity and efficacy in various cancers, including non-small cell lung cancer.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Epidermal Growth Factor (EGF) receptor tyrosine kinase signaling pathways are crucial in cancer cell proliferation.
  • Targeting these pathways offers a therapeutic strategy for various malignancies.

Purpose of the Study:

  • To evaluate the efficacy and safety of ZD 1839, a specific EGF receptor tyrosine kinase inhibitor.
  • To assess the pharmacokinetic profile and antiproliferative effects of ZD 1839.

Main Methods:

  • Preclinical studies assessing efficacy and bioavailability.
  • Phase I clinical trials in healthy volunteers and cancer patients to determine safety, tolerability, and pharmacokinetics.
  • Evaluation of clinical responses in patients with various malignant tumors.

Related Experiment Videos

Main Results:

  • ZD 1839 demonstrated good bioavailability and a terminal half-life of 27-41 hours, allowing single oral dosing.
  • Excellent tolerance in healthy volunteers and manageable toxicity in Phase I studies.
  • Observed clinical responses in patients with malignant tumors, notably non-small cell lung cancer.

Conclusions:

  • ZD 1839 is a well-tolerated and effective inhibitor of the EGF receptor tyrosine kinase.
  • The drug exhibits promising antiproliferative effects and warrants further investigation in Phase II and III trials for various cancers.